SynthesisTranslational psychiatry2020
A systematic review and narrative synthesis of data-driven studies in schizophrenia symptoms and cognitive deficits.
Synthesis in Translational psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07196423 (Glutamate Changes as a New Neurocognitive Marker in Psychosis), which is not on this map. Cited by 59 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Glutamate Changes as a New Neurocognitive Marker in Psychosis
Who cites it
59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Meta-analysis of Face Perception in Schizophrenia Spectrum Disorders: Evidence for Differential Impairment in Emotion Face Perception.Schizophrenia bulletin · 2024Pooled it
- Pooled it
- Assessing cognition in people with severe mental disorders in low- and middle-income countries: a systematic review of assessment measures.Social psychiatry and psychiatric epidemiology · 2022Pooled it
- Frontal neural metabolite changes in schizophrenia and their association with cognitive control: A systematic review.Neuroscience and biobehavioral reviews · 2022Pooled it
- Childhood premorbid adjustment as a marker for 20-year impairments in schizophrenia spectrum disorder: results from the OPUS study.European child & adolescent psychiatry · 2026Trial
- Long-Term Trajectories of Multidimensional Outcomes in Psychosis Following Early Intervention During the Critical Period: The PEPP-Montreal 10+ Study Protocol.Early intervention in psychiatry · 2026Article
- Neuroimaging-Based Subgroups in Schizophrenia: A Critical Appraisal of Clustering Studies.Biological psychiatry global open science · 2026Review
- Premorbid functioning trajectories and the one-year course of cognitive performance in first-episode psychosis: a cluster analysis in PSYSCAN.Schizophrenia research. Cognition · 2026Article
- Social inclusion profiles in first episode psychosis and their links to social cognition and symptoms: A cluster analysis approach.Social psychiatry and psychiatric epidemiology · 2026Article
- The kynurenine pathway in depression and schizophrenia: convergent signals, divergent states, and clinical signatures.EXCLI journal · 2026Review
- An umbrella review of psychological capacity and mental health trajectories across the life course.Nature. Mental health · 2026Article
- A comprehensive review on schizophrenia: epidemiology, pathogenesis, diagnosis, conventional treatments, and proposed natural compounds used for management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Differences in Performance in the Trail Making Test Part B Between Adoptees With High and Low Genetic Risk for Schizophrenia Spectrum Disorders: The Finnish Adoptive Family Study of Schizophrenia.The European journal of neuroscience · 2025Article
- Latent Trajectories of Positive, Negative Symptoms and Functioning in Early Intervention Services for First-Episode Psychosis: A 2-Year Follow-Up Study.Schizophrenia bulletin · 2025Article
- Practical AI application in psychiatry: historical review and future directions.Molecular psychiatry · 2025Review
- Effects of Risperidone and Aripiprazole Antipsychotic Drugs on Behavioral Changes and the Expression Levels of DRD2, HTR2A, AKT1, and CACNA1C Genes in the Hippocampus of a Ketamine-induced Schizophrenia-like Rat Model.Journal of molecular neuroscience : MN · 2025Article
- Validation and normative data for the BAC app in Spanish-speaking individuals with psychosis and healthy controls.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- Sex differences in schizophrenia spectrum disorders: insights from the DiAPAson study using a data-driven approach.Social psychiatry and psychiatric epidemiology · 2025Article
- Dual inflammation in schizophrenia infected with COVID-19: Impact on cognitive function.Brain, behavior, & immunity - health · 2025Article
- Polygenic Scores for Schizophrenia and Educational Attainment Predict Global Functioning Across Psychiatric Hospitalization Among People with Schizophrenia.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
To tackle the phenotypic heterogeneity of schizophrenia, data-driven methods are often applied to identify subtypes of its symptoms and cognitive deficits. However, a systematic review on this topic is lacking. The objective of this review was to summarize the evidence obtained from longitudinal and cross-sectional data-driven studies in positive and negative symptoms and cognitive deficits in patients with schizophrenia spectrum disorders, their unaffected siblings and healthy controls or individuals from general population. Additionally, we aimed to highlight methodological gaps across studies and point out future directions to optimize the translatability of evidence from data-driven studies. A systematic review was performed through searching PsycINFO, PubMed, PsycTESTS, PsycARTICLES, SCOPUS, EMBASE and Web of Science electronic databases. Both longitudinal and cross-sectional studies published from 2008 to 2019, which reported at least two statistically derived clusters or trajectories were included. Two reviewers independently screened and extracted the data. In this review, 53 studies (19 longitudinal and 34 cross-sectional) that conducted among 17,822 patients, 8729 unaffected siblings and 5520 controls or general population were included. Most longitudinal studies found four trajectories that characterized by stability, progressive deterioration, relapsing and progressive amelioration of symptoms and cognitive function. Cross-sectional studies commonly identified three clusters with low, intermediate (mixed) and high psychotic symptoms and cognitive profiles. Moreover, identified subgroups were predicted by numerous genetic, sociodemographic and clinical factors. Our findings indicate that schizophrenia symptoms and cognitive deficits are heterogeneous, although methodological limitations across studies are observed. Identified clusters and trajectories along with their predictors may be used to base the implementation of personalized treatment and develop a risk prediction model for high-risk individuals with prodromal symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.